Electrophysiologic Mechanisms of Ketamine Antidepressant Response

Part of paid clinical trials in Atlanta, Georgia.

Sponsor: Emory University
Study ID: NCT07768618
Phase: PHASE2
Status: Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Depressive Symptoms
Epilepsy

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Ketamine — DRUG
Participants will receive one subanesthetic intravenous ketamine infusion administered at a dose of 0.5 mg/kg over 40 minutes during admission to the Epilepsy Monitoring Unit. The infusion will be supervised by a psychiatrist experienced in ketamine administration and conducted under continuous clinical monitoring. Intracranial sEEG recordings, behavioral assessments, and symptom measures collected before and approximately 24 hours after infusion will be used to evaluate electrophysiologic biomarkers associated with antidepressant response

Study Details

This study aims to identify electrophysiologic biomarkers associated with antidepressant response to ketamine in adults with epilepsy undergoing clinically indicated stereo-electroencephalography (sEEG) monitoring who have at least mild depressive symptoms. Participants will receive a single subanesthetic intravenous ketamine infusion (0.5 mg/kg over 40 minutes) during their Epilepsy Monitoring Unit admission. Intracranial neural recordings and behavioral assessments will be collected before and approximately 24 hours after infusion to examine changes in neural circuits associated with rumination and anhedonia.

Key Dates

First listed: Aug 17, 2026
Start date: Dec 31, 2026
Status verified: Aug 2026
Primary completion: Dec 31, 2031
Completion: Dec 31, 2031

Study Design

Enrollment: 37 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Arms

Experimental: Intravenous Ketamine During sEEG Monitoring
Adults undergoing clinically indicated sEEG monitoring for epilepsy who have at least mild depressive symptoms will receive a single intravenous ketamine infusion (0.5 mg/kg over 40 minutes). Neural, behavioral, and symptom assessments will be performed before and approximately 24 hours after infusion to evaluate electrophysiologic correlates of antidepressant response.